Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack
Cellular Physiology and Biochemistry · 21.08.2024 · 58 (4) · 418-430
DOI: 10.33594/000000721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Physiology and Biochemistry, online erschienen am 21.08.2024. Verfasst von Jin Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Mice, Inbred C57BL, Ceramides, Apoptosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background/Aims: After 9/11, multiple government agencies instituted programs aimed at developing medical radiation countermeasures (MRCs) for two syndromes lethal within weeks of a limited nuclear attack; the hematopoietic-acute radiation syndrome (H-ARS) and the higher-dose gastrointestinal-acute radiation syndrome (GI-ARS). While re-purposing drugs that enhance marrow repopulation treats H-ARS, no mitigator protects GI tract.
Methods
We recently reported anti-ceramide 6B5 single-chain variable fragment (scFv) pre-treatment abrogates ongoing small intestinal endothelial apoptosis to rescue Lgr5+ stem cells, preventing GI-ARS lethality in C57B/L6J mice. Here, with US Department of Defense support, we provide evidence that humanized anti-ceramide scFv (CX-01) is a promising prophylactic MRC for first responders, who risk exposure upon entering a radiation-contaminated site.
Results
CX-01, when delivered up to 90 min before irradiation, is highly-effective in preventing small intestinal endothelial apoptosis in mice and lethality in both sexes. Unexpectedly, females require an ~2-fold higher CX-01 dose than males for full protection. CX-01 is effective subcutaneously and intramuscularly, a property critical for battlefield use. Increasing the maximally-effective dose 5-fold does not extend duration of bioeffectiveness.
Conclusion
While CX-01 prevents GI-ARS lethality, structural modification to extend half-life may be necessary to optimize first responder prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
- Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
- The Champalimaud Center, Lisbon, Portugal.
- Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, New York, USA, r-kolesnick@ski-mskcc.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Cheng, J., Nagesh, P. K. B., Feldman, R., Shamu, T., Zhang, Z., Fuks, Z., & Kolesnick, R. (2024). Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack. Cellular Physiology and Biochemistry, 58(4), 418-430. https://doi.org/10.33594/000000721
Vancouver
Cheng J, Nagesh PKB, Feldman R, Shamu T, Zhang Z, Fuks Z, et al. Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack. Cellular Physiology and Biochemistry. 2024;58(4):418-430. doi:10.33594/000000721
BibTeX
@article{Cheng2024,
author = {Cheng, Jin and Nagesh, Prashanth K B and Feldman, Regina and Shamu, Tambudzai and Zhang, Zhigang and Fuks, Zvi and Kolesnick, Richard},
title = {Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack},
journal = {Cellular Physiology and Biochemistry},
year = {2024},
volume = {58},
number = {4},
pages = {418--430},
doi = {10.33594/000000721}
}
EUVIMED